[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s First Quarter Sales 2024 Presentation
Roche will publish its Sales Results for the 1st Quarter 2024 prior to the opening of the Swiss Stock Exchange onWednesday, 24 April 2024. 07:00 CEST / 06:00BST / 01:00 AM EDT / 10:00 PM PDT (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here 14:00 – 15:30 CEST / 13:00 – 14:30 BST08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDTThe webinar will start with presentations by senior management, followed by a Q&A session.Presenters:Thomas Schinecker, CEO Roche GroupAlan Hippe, Chief Financial and IT Officer Ro...
Source: Roche Investor Update - April 17, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphomaData from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meetingBasel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates fo...
Source: Roche Investor Update - April 15, 2024 Category: Pharmaceuticals Source Type: news
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
The Elecsys ® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in identifying amyloid pathology, a key feature of Alzheimer ’s diseaseRoche and Lilly believe the test could play an important role in improving access to early and accurate Alzheimer ’s diagnosisBasel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed ...
Source: Roche Investor Update - April 11, 2024 Category: Pharmaceuticals Source Type: news
Invitation: Roche Diagnostics Investor Day 2024
The Roche Investor Relations team would like to invite you to the Roche Diagnostics Investor Day that will take place in London on Wednesday, 22 May 2024, starting at 12:00 BST local time and will finish at 15:30 BST with a reception.The Roche Diagnostics Investor Day will address the following topics:Mass spectrometryContinuous glucose monitoringNext generation sequencingPoint of careUpcoming molecular diagnostics launchesNeurology biomarkers in development Presenters include:Matt Sause, CEO Roche DiagnosticsAlan Hippe, Chief Financial and IT OfficerPalani Kumaresan, Global Head of Roche Diagnostics Solutions (RDS)B...
Source: Roche Investor Update - April 10, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Chugai: Piasky (crovalimab) for Paroxysmal Nocturnal Hemoglobinuria approved in Japan
Dear Investor,Please find attached a press release by Chugai:https://www.roche.com/240326_Chugai_ePiasky_EN.pdfDo not hesitate to contact us for any further questions.With best regards,Roche Investor Relations Dr. Bruno EschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabine Borngr äberPhone: +41 61 68-88027e-mail:sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail:birgit.masjost@roche.com Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail:kalm.loren@gene.com (Source: Roche Investor Update)
Source: Roche Investor Update - March 26, 2024 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by mosquitoes that can also be spread through blood transfusionRoche is dedicated to saving patients ’ lives through diagnostic solutions that aid in the protection of the global blood supply from infectious diseasesBasel, 26 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of the cobas® Malaria test for use on the cobas® 6800/8800 Systems. This approved test ca...
Source: Roche Investor Update - March 26, 2024 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s First Quarter Sales 2024 Presentation
Roche will publish its Sales Results for the 1st Quarter 2024 prior to the opening of the Swiss Stock Exchange onWednesday, 24 April 2024. 07:00 CEST / 06:00BST / 01:00 AM EDT / 10:00 PM PDT (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here 14:00 – 15:30 CEST / 13:00 – 14:30 BST08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDTThe webinar will start with presentations by senior management, followed by a Q&A session.Presenters:Thomas Schinecker, CEO Roche GroupAlan Hippe, Chief Financial and IT Officer ...
Source: Roche Investor Update - March 22, 2024 Category: Pharmaceuticals Source Type: news
Alnylam to webcast investor event to discuss results from KARDIA-2 phase 2 study of zilebesiran at American College of Cardiology Scientific Session
Dear Investor,Please find below link to a press release from our partner company Alnylam:https://investors.alnylam.com/press-release?id=28071We kindly invite you to join this investor event on Sunday April 7, 2024 at 7:00 pm ET.Do not hesitate to contact us for any further questions.With best regards,Roche Investor Relations Dr. Bruno EschliPhone: +41 61 68-75284e-mail:bruno.eschli@roche.com Dr. Sabine Borngr äberPhone: +41 61 68-88027e-mail:sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail:birgit.masjost@roche.com Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail:k...
Source: Roche Investor Update - March 20, 2024 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive agreement with Lonza, which will acquire the Genentech manufacturing facility in Vacaville, California, USA
Basel, 20 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive agreement with Lonza, under which Lonza will acquire the Genentech manufacturing facility in Vacaville, California, USA, for USD 1.2 billion in conjunction with a manufacturing agreement and related quality services and warehousing.Under the terms of the agreement, the approximately 750 Genentech employees at the Vacaville facility will be offered employment by Lonza and the products currently produced at the site by Roche will continue to be supplied by Lonza for a transition period.“We decided to divest our V...
Source: Roche Investor Update - March 20, 2024 Category: Pharmaceuticals Source Type: news
Roche Annual General Meeting 2024
All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend increase to CHF 9.60 per shareBasel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders in attendance, who represented 77.02% of the total 106,691,000 shares, approved the Annual Financial Statements and Co nsolidated Financial Statements for 2023, the Remuneration Report and the Sustainabi...
Source: Roche Investor Update - March 12, 2024 Category: Pharmaceuticals Source Type: news
Roche presents positive topline CGM accuracy data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
At the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, Roche shared recent accuracy data for its new Accu-Chek SmartGuide solution for real-time continuous glucose monitoring (rtCGM)International experts discussed how a novel CGM solution using prediction capabilities can address unmet needs of people with diabetes at the Roche symposiumThe presented study results underlined the accurate and safe performance of the solutionBasel, 7 March, 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented the latest data on its novel solution for continuous glucose monitoring. ...
Source: Roche Investor Update - March 7, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news
